- Home
- MYND vs HOWL Comparison
MYND vs HOWL Comparison
Compare MYND & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | HOWL |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 15.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYND | HOWL |
|---|---|---|
| Price | $0.41 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 35.0K | ★ 866.2K |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.27 |
| 52 Week High | $1.15 | $2.23 |
Technical Indicators
Market Signals| Indicator | MYND | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 38.40 |
| Support Level | $0.29 | N/A |
| Resistance Level | $0.51 | $0.75 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.29 | 48.25 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.